The utility of fluorescence in situ hybridization analysis in diagnosing myelodysplastic syndromes is limited to cases with karyotype failure-Reference-Cited by-同舟云学术

The utility of fluorescence in situ hybridization analysis in diagnosing myelodysplastic syndromes is limited to cases with karyotype failure

Published:2012-04 Issue:4 Volume:36 Page:448-452
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Jiang Hui,Xue Yongquan,Wang Qinrong,Pan Jinlan,Wu Yafang,Zhang Jun,Bai Shuxiao,Wang Qian,He Guangsheng,Sun Aining,Wu Depei,Chen Suning

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference28 articles.

1. WHO classification of tumours of haematopoietic and lymphoid tissues;Swerdlow,2008

2. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients;Haase;Blood,2007

3. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes;Solé;Haematologica,2005

4. Cytogenetic features in myelodysplastic syndromes;Haase;Ann Hematol,2008

5. FISH and SNP-A karyotyping in myelodysplastic syndromes: improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q);Makishima;Leuk Res,2010

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Shallow whole‐genome sequencing of bone marrow aspirates in myelodysplastic neoplasms: A retrospective comparison with cytogenetics;Genes, Chromosomes and Cancer;2023-06-09

2. Hematopathology;Oncological Surgical Pathology;2020

3. Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms;Cancer Genetics;2018-12

4. Is fluorescence in-situ hybridization sufficient in patients with myelodysplastic syndromes and insufficient cytogenetic testing?;Leukemia & Lymphoma;2018-09-06

5. Observing DNA in live cells;Biochemical Society Transactions;2018-06-05